Search all ALPCO products, resources, and website information

June 19, 2018 ALPCO, a leading producer of research and clinical immunoassays, announced it will showcase its new STELLUX® Chemi Active GLP-1 (7-36) amide ELISA at the American Diabetes Association’s 78th Scientific Sessions June 23-25, 2018 in Orlando, FL.  This new addition to the STELLUX® Chem...

ALPCO announced in a press release on January 22, 2014 that their test portfolio for clinical and hospital laboratory customers has expanded to include a new FDA 510(k) cleared 25-OH Vitamin D Total ELISA. The growth in 25-OH Vitamin D testing has been a challenge for clinical and hospital labora...

Datasheet: Complement System Immunoassays Download The complement system is essential to innate immunity which protects from chronic, autoimmune, and infectious disease. There are three distinct pathways of complement activation: classical, lectin/MBL, and alternative. Each leads...

Bone metabolism is a continual cycle of bone growth and resorption that is carefully orchestrated by the dynamic relationship between osteoclasts, osteoblasts and an array of hormonal and regulatory influences. The relative levels of these signaling molecules dictate whether healthy, balanced bo...

Drug-Induced Organ Injury Toxicological side effects are a common obstacle in drug development pipelines and often manifest in site-specific damage to vital organs, including the liver, kidney and heart. Estimates of compound attrition from failure to meet safety endpoints are as high as 45% in pre...

Date: July 21, 2015 Author: Bethany Bell, PhD; Senior Product Manager at ALPCO Dr. Anders Berg presented at the Northeast Laboratory Conference in October 2014 regarding a much debated topic: vitamin D deficiency and how this should be defined. Dr. Berg referenced over one thousand studies, re...

Introduction The prevalence of diabetes and obesity has been on the rise for several decades and research has demonstrated that other parts of the body, including the cardiovascular system and kidneys, can be affected by diabetes. The key to understanding the relationship between diabetes and the...

Date: July 1, 2015 ALPCO is pleased to announce a strategic account sales and distribution agreement with Cisbio US, Inc. Cisbio will now have exclusive access to ALPCO’s high quality STELLUX® Chemiluminescence and colorimetric Diabetes and Obesity assay portfolio in order to provide these produc...

Date: January 26, 2016 ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step. The unique extraction method allows laboratories to improve their sample processing time by up to 86% by extracting one sample for up to 13...

ALPCO is now offering a new broad range Periostin ELISA that has been optimized to detect all known splicing forms of human periostin. The Periostin ELISA is highly characterized with a full validation package, and offers great reproducibility and precision. Not only are all standards and controls i...

Date: June 21, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Several therapies exist to help treat inflammatory bowel disease (IBD) and improve patient quality of life. However, a growing number of gastroenterologists and patients have been choosing to stop these therapies -...

Date: July 26, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Over the past several years, the drug arsenal to combat B cell cancers has gained a mighty weapon: Bruton’s tyrosine kinase (BTK) inhibitors. The origins of using BTK inhibitors as cancer drug treatments actually b...

Date: August 16, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Bruton’s tyrosine kinase (BTK) inhibitors are not the only kinase inhibitors to enter the fight against B cell cancers. Since there are numerous subtypes of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), p...

Date: September 6, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO Signaling pathways dictate the differentiation, activation, and functions of immune cells.  Even the slightest problem in one cell signaling pathway can transform the immune system and turn it against the body,...

Date: September 27, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO From cosmetics to water bottles, endocrine disrupting chemicals (EDCs) have surfaced in our everyday lives. EDCs are compounds that can interfere with the endocrine system’s ability to help an organism develop...

We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac dis...

Nobel Prize winning British chemist Dr. Dorothy Hodgkin significantly contributed to unraveling the secrets of diabetes mellitus. She is considered a founder of X-ray crystallography, a technique used to discern the structures of organic biomolecules. Dorothy Hodgkin’s discovery of insulin's 3D...

Biologics have been commonly prescribed as therapies for inflammatory bowel disease (IBD) since the late 1990s. However, research demonstrates that not all individuals respond to the first biologic taken and many lose response over time1. As a result, there is a great need to explore the immunogenic...

Watch our video to learn more about the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and how you can now measure this incretin hormone with confidence. https://www.youtube.com/watch?v=Chu3VhEEpt0&t=3s The STELLUX® Chemi Active GLP-1 (7-36) amide ELISA features increased sensitivity to ac...

July 25, 2018 ALPCO will exhibit at the AACC’s 70th Annual Clinical Lab Expo July 31-August 2, 2018 in Chicago, IL. The company will promote a number of tools to help research and improve clinical outcomes as well as increase laboratory efficiency. Among these tools are new and upcoming additi...